Roth Capital Affirms Regeneron (REGN) at 'Buy' Following Eylea Phase 2 Data in Wet-AMD

September 30, 2016 10:16 AM EDT
Get Alerts REGN Hot Sheet
Price: $363.53 -2.08%

Rating Summary:
    19 Buy, 18 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade REGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Roth Capital reaffirms Regeneron (Nasdaq: REGN) at Buy with a price target of $520 following news that Phase II CAPELLA trial for wet-AMD missed its primary endpoint.

Analyst Joseph Pantginis commented, Today’s announcement by REGN is an unfortunate event that refocuses its efforts on eye disease to the aflibercept/nesvacumab combination therapy. However it continues to point to Eylea's continued strong efficacy as a monotherapy. At the present Regeneron and Bayer (BAYN-NC) are jointly developing and evaluating the combination therapy and it is currently in two Phase II clinical trials for intravitreal injection in patients with wet age-related macular degeneration and diabetic macular edema.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital

Add Your Comment